Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for oral administration of exenatide

a technology of exenatide and composition, which is applied in the direction of drug composition, peptide/protein ingredient, metabolic disorder, etc., can solve the problems of low patient compliance of parenterally administered peptide drugs, relative ineffectiveness of peptide drugs given perorally, and blood sugar to become too low, so as to reduce food intake, reduce food intake in a subject, and reduce gastric motility

Inactive Publication Date: 2011-02-24
ORAMED
View PDF8 Cites 130 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]In another embodiment, the present invention provides a method for reducing food intake in a subject, comprising administering orally or rectally to a subject a pharmaceutical composition comprising exenatide, thereby reducing food intake in a subject.
[0017]In another embodiment, the present invention provides a method for reducing gastric motility in a subject, comprising administering orally or rectally to a subject a pharmaceutical composition comprising exenatide, thereby reducing gastric motility in a subject.
[0018]In another embodiment, the present invention provides a method for lowering plasma glucagon in a subject, comprising administering orally or rectally to said subject a pharmaceutical composition comprising exenatide, thereby lowering plasma glucagon in a subject.

Problems solved by technology

However, a limiting factor in the development of peptide drugs is the relative ineffectiveness when given perorally.
Almost all peptide drugs are parenterally administered, although parenterally administered peptide drugs are often connected with low patient compliance.
Once blood sugar levels decrease closer to normal values, the pancreas response to produce insulin is reduced; however, other drugs (like injectable insulin) are effective at lowering blood sugar, but can “overshoot” their target and cause blood sugar to become too low, resulting in the dangerous condition of hypoglycemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for oral administration of exenatide
  • Methods and compositions for oral administration of exenatide

Examples

Experimental program
Comparison scheme
Effect test

example 1

Protection of Exenatide from Proteases and Successful Administration Via the Duodenum in Dogs

Materials and Experimental methods

Formulations

[0095](1) A formulation containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 50 μg exenatide, and 0.8 milliliter (ml) fish oil was prepared.

[0096]A formulation containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 100 μg exenatide, and 0.8 milliliter (ml) fish oil was prepared.

[0097](3) A formulation containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 0.8 milliliter (ml) fish oil was prepared.

Results

[0098]To test whether exenatide can be protected from proteases and absorbed via the duodenum, formulation 1 (treatment) or 3 (control) were administered directly to the duodenum of about 9 kg beagle dogs or by an endoscope to about 16 kg pigs.

[0099]All dog...

example 2

Injectable Dosage Forms Compared to Rectal and Oral Dosage Forms

Materials and Experimental Methods

Formulation

[0102]The following formulations were prepared:[0103](1) An injectable formulation comprising 2.5 μg commercial byetta.[0104](2) An injectable formulation comprising 2.5 μg GeneScript (Piscataway, N.J.) byetta.[0105](3) An oral formulation containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 50 μg exenatide (GeneScript (Piscataway, N.J.)) and 0.8 milliliter (nil) fish oil.[0106](4) An oral formulation containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 0.8 milliliter (ml) fish oil.[0107](5) A hard gelatin capsule (rectal) containing 150 milligram (mg) Na-EDTA (Sigma-Aldrich, St. Louis, Mo.), 125 mg soybean trypsin inhibitor (SBTI; Sigma), 50 μg exenatide (GeneScript (Piscataway, N.J.)) and in 0.8 milliliter (ml) fish oil.

Results

[0108]To test the...

example 3

Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs with a Formulation Which Facilitates the Absorption of Exenatide-4 Across Biological Membranes

Materials and Experimental Methods

[0113]Study was conducted in 4 beagle dogs with an average weight of 10 kg. All the dogs had a cannula residing in the jejunum through which the drug was administered. After an overnight fast, the dogs were given different doses of oral GLP-1 analogue or sc injection of the analogue. Absorption of the GLP-1 analogue was assessed by measuring the effect on glucose excursion following an oral glucose load. Control experiment consisted of oral dosing without administration of GLP-1 analogue. The interval between oral administration and the oral glucose load was 30 minutes. The primary efficacy end point was the glucose excursion above the pre-OGTT glucose level over a 150 min interval (incremental area under the curve (AUC)0-150 min).

Results

[0114]Direct jejunal instillation o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
resistanceaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.

Description

FIELD OF INVENTION[0001]This invention provides oral compositions comprising Exenatide, and a method for administering same.BACKGROUND OF THE INVENTION[0002]Due to improved biotechnology, the accessibility of biologically active peptides to the pharmaceutical industry has increased considerably. However, a limiting factor in the development of peptide drugs is the relative ineffectiveness when given perorally. Almost all peptide drugs are parenterally administered, although parenterally administered peptide drugs are often connected with low patient compliance.[0003]Exenatide is a glucagon-like peptide (GLP-1) agonist that was approved by the Food and Drug Administration for adjunctive therapy when patients with type 2 diabetes have not been optimally controlled on metformin. It is an incretin mimetic and potentiates exenatide secretion while inhibiting glucagon secretion and slowing gastric emptying.[0004]Exenatide (marketed as Byetta) is manufactured and marketed by Amylin Pharmac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22A61P3/10
CPCA61K9/0031A61K38/56A61K9/4866A61K31/202A61K31/22A61K38/26A61K38/57A61K9/2846A61K9/0053A61K2300/00A61K9/2013A61K9/2853A61K9/4858A61K38/22A61K47/12A61P1/00A61P19/02A61P3/04A61P43/00A61P5/48A61P5/50A61P9/10A61P9/12A61P3/10
Inventor KIDRON, MIRIAM
Owner ORAMED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com